Regimen confers ‘meaningful’ benefit in aggressive lymphoma, may become a new standard

CHICAGO — The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND trial.The combination of tafasitamab (Monjuvi, Incyte), lenalidomide and R-CHOP reduced risk for progression or death by 25% compared with R-CHOP alone among patients with newly diagnosed

Raccontata dahealio.commedpagetoday.commorningstar.comecodibergamo.it